LumiThera Inc., a Seattle, WA-based clinical stage private medical device company creating a non-invasive photobiomodulation (PBM) treatment for ocular disorders and diseases, completed a Series B round of financing raising $5.5M.
The round was led by WaterStone Capital, with participation from RPR Venture. In conjunction with the funding, WaterStone Capital’s founding partner, Yigang Yang, will be joining LumiThera’s Board of Directors.
The company intends to use the funds to further develop of the LT-300 device for the treatment of dry Age-related Macular Degeneration (AMD) by obtaining regulatory clearances in select countries outside the USA including the CE Mark in Europe and expand its additional clinical and commercial activities.
Led by Clark Tedford, Ph.D., President and CEO, LumiThera is a clinical-stage medical device company focused on the use of photobiomodulation, using non-invasive light emitting diodes to treat patients with acute and chronic ocular diseases and disorders.
The company is currently developing an ophthalmologist LED office-based instrument to be used in treating dry Age-related Macular Degeneration via a prospective, randomized, double masked, clinical trial in 30 dry AMD subjects called the LIGHTSITE I study with the LumiThera LT-300 light delivery system.